1. Home
  2. SLN vs YRD Comparison

SLN vs YRD Comparison

Compare SLN & YRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • YRD
  • Stock Information
  • Founded
  • SLN 1994
  • YRD 2012
  • Country
  • SLN United Kingdom
  • YRD China
  • Employees
  • SLN N/A
  • YRD N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • YRD Finance: Consumer Services
  • Sector
  • SLN Health Care
  • YRD Finance
  • Exchange
  • SLN Nasdaq
  • YRD Nasdaq
  • Market Cap
  • SLN 223.4M
  • YRD 411.2M
  • IPO Year
  • SLN N/A
  • YRD 2015
  • Fundamental
  • Price
  • SLN $4.23
  • YRD $6.73
  • Analyst Decision
  • SLN Buy
  • YRD
  • Analyst Count
  • SLN 5
  • YRD 0
  • Target Price
  • SLN $40.80
  • YRD N/A
  • AVG Volume (30 Days)
  • SLN 282.3K
  • YRD 155.8K
  • Earning Date
  • SLN 02-27-2025
  • YRD 03-20-2025
  • Dividend Yield
  • SLN N/A
  • YRD 2.53%
  • EPS Growth
  • SLN N/A
  • YRD N/A
  • EPS
  • SLN N/A
  • YRD 2.95
  • Revenue
  • SLN $43,258,000.00
  • YRD $802,340,579.00
  • Revenue This Year
  • SLN N/A
  • YRD N/A
  • Revenue Next Year
  • SLN N/A
  • YRD N/A
  • P/E Ratio
  • SLN N/A
  • YRD $2.20
  • Revenue Growth
  • SLN 36.71
  • YRD 19.51
  • 52 Week Low
  • SLN $4.06
  • YRD $4.12
  • 52 Week High
  • SLN $27.72
  • YRD $9.20
  • Technical
  • Relative Strength Index (RSI)
  • SLN 41.17
  • YRD 53.09
  • Support Level
  • SLN $4.10
  • YRD $6.38
  • Resistance Level
  • SLN $5.23
  • YRD $7.16
  • Average True Range (ATR)
  • SLN 0.40
  • YRD 0.45
  • MACD
  • SLN 0.06
  • YRD -0.09
  • Stochastic Oscillator
  • SLN 33.90
  • YRD 36.12

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About YRD Yiren Digital Ltd.

Yiren Digital Ltd is an advanced, AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.

Share on Social Networks: